Millipore, Novo Nordisk extend insulin agreement

BILLERICA, Mass. Millipore and Novo Nordisk have agreed to extend their agreement for several more years to provide the biopharmaceutical market with recombinant human insulin.

Millipore gains worldwide rights to market and sell the human insulin as brand name Incelligent SG and Incelligent AF for cell culture media applications. The drug is used as a key cell supplement to manufacture biologic drugs. Incelligent is available in an animal free version, which reduces the risks and eases regulatory concerns for biopharmaceutical manufacturers.

"We are delighted to announce the expansion of our long-standing partnership with Novo Nordisk," said Andrew Bulpin, Ph.D., Vice President of Millipore’s Bio-Products and Technologies Business Unit. "It confirms both companies’ commitment to supply animal-free, recombinant insulin to biopharmaceutical manufacturers for the long-term."